| Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment. | |
| | |
MedLine Citation:
|
PMID: 15985755 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Postnatal alterations in pulmonary mechanics, energetics and functional residual capacity (FRC) describe the structural maturation of the preterm respiratory system. OBJECTIVE: To evaluate longitudinal changes in pulmonary function in infants with respiratory distress syndrome (RDS) treated with oxygen, positive pressure ventilation and synthetic surfactant (Exosurf). METHODS: Serial pulmonary function tests were performed in surfactant-treated infants [mean +/- SD birth weight (BW) = 1,112 +/- 276 g, gestational age (GA) = 29 +/- 3 weeks] at postnatal ages: <3 days, 1, 2, 3, 4 and 6-8 weeks until term postmenstrual age (PMA). Tidal volume, pulmonary compliance (C(L)), pulmonary resistance (R(T)) and flow-resistive work were analyzed following simultaneous measurements of airflow and transpulmonary pressure signals. Serial FRC measurements were made in a randomly selected group. Results: Prior to 28 weeks' PMA, C(L) was unchanged irrespective of GA. At age 1 week the likelihood ratio (LR) for bronchopulmonary dysplasia (BPD) based on C(L), R(T) and GA was predicted to be >90% for those with BW <750 g (LR >100) as compared to <10% probability (LR = 0.3) for infants >1,500 g. Significant linear increase in C(L) to PMA was evident >28 weeks' PMA (r = 0.86, p < 0.01) at 0.17 ml/cm H2O/kg/week. By term PMA, mean C(L) was 2.60 +/- 0.07 ml/cm H2O. Improvements in FRC of preterm infants with RDS who recovered occur at a more rapid rate ( approximately 25 ml/kg) compared to those who developed BPD ( approximately 20 ml/kg). CONCLUSIONS: Slow but incremental postnatal pulmonary improvement, minimal <28 weeks' PMA, were comparable for all infants. Along with diminished FRC, these changes reflect persistent deleterious effects of positive pressure ventilation, alveolar hyperoxia and unrecognized pulmonary overdistension. |
| | |
Authors:
|
Vinod K Bhutani; Frank W Bowen; Emidio M Sivieri |
Related Documents
:
|
22044425 - B-type natriuretic peptide levels at birth predict cardiac dysfunction in neonates. 18419895 - Neonatal pulmonary tuberculosis evolving to a destroyed lung. 11126265 - Is leukocytosis a predictor of mortality in severe pertussis infection? 6399015 - Pneumomediastinum: a diagnostic problem. 20607645 - Swallow-breath interaction and phase of respiration with swallow during nonnutritive su... 9137345 - Effects of suboptimal intra-uterine growth on preterm infants between 30 and 32 weeks' ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2005-06-01 |
Journal Detail:
|
Title: Biology of the neonate Volume: 87 ISSN: 0006-3126 ISO Abbreviation: Biol. Neonate Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-06-29 Completed Date: 2005-08-19 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0247551 Medline TA: Biol Neonate Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 323-31 Citation Subset: IM |
Copyright Information:
|
Copyright 2005 S. Karger AG, Basel |
Affiliation:
|
Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, CA 94305-5731, USA. bhutani@stanford.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Continuous Positive Airway Pressure Drug Combinations Fatty Alcohols / administration & dosage, therapeutic use* Humans Infant, Newborn Infant, Premature Longitudinal Studies Oxygen / administration & dosage Phosphorylcholine / administration & dosage, therapeutic use* Polyethylene Glycols / administration & dosage, therapeutic use* Pulmonary Surfactants / administration & dosage, therapeutic use* Respiratory Distress Syndrome, Newborn / drug therapy*, physiopathology* Respiratory Function Tests Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/Fatty Alcohols; 0/Polyethylene Glycols; 0/Pulmonary Surfactants; 107-73-3/Phosphorylcholine; 7782-44-7/Oxygen; 99732-49-7/Exosurf |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: History of surfactant from 1980.
Next Document: New synthetic surfactants--basic science.